Atlas Trials

A Study to Learn More About How Safe Darolutamide is Under Real-world Conditions in Participants With Metastatic Hormone-Sensitive Prostate Cancer

Clinical trial NCT06010914 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT06010914
Sponsor
Bayer
Status
ACTIVE_NOT_RECRUITING
Study type
OBSERVATIONAL
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Start date
2023-10-09
Primary completion
2026-03-16
Enrollment
100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.